The injection era for obesity drugs may not be ending. But it just got a serious competitor.
Here’s what happened. The FDA granted approval to orforglipron — now marketed as Foundayo — Eli Lilly’s once-daily oral GLP-1 receptor agonist for chronic weight management in adults with obesity or those overweight with at least one weight-related comorbidity. What makes this different from Novo Nordisk’s oral Wegovy, which launched in January? Foundayo is the first GLP-1 obesity pill with no food or water restrictions. You don’t have to take it on an empty stomach and wait 30 minutes. That sounds small. It isn’t.
Lilly’s CEO David Ricks put it plainly: “Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn’t serious enough for treatment.”
That number — 1 in 10 — is the only number that actually matters here. The entire market debate has been about Lilly vs. Novo. The bigger debate should be about the 90% of the addressable population who aren’t using any of these drugs at all.
The oral GLP-1 market is expected to capture around 20% of the $80 billion obesity GLP-1 market by the end of the decade. That’s $16 billion in a product category that barely existed 18 months ago. And that estimate was built before either pill was actually on pharmacy shelves.
Here’s where most investors are stopping the analysis. They’re tracking the horse race — Lilly vs. Novo, efficacy comparisons, pricing. In terms of efficacy, the Wegovy pill led to 13.6% weight loss in a 64-week Phase 3 trial, slightly more than the 11.2% weight loss orforglipron showed in its 72-week study. Novo wins on weight loss data. Lilly wins on convenience. And both of them win if the market expands, which it almost certainly will.
The part people are skipping is the downstream supply chain. Oral pills don’t require cold storage. They don’t require trained healthcare staff for administration. While the daily oral treatments are generally seen to be less effective than the weekly injectables, they’re still expected to have wide appeal since many people don’t want to use needles, and the pills can be easily distributed and don’t require cold storage.
That changes the distribution math entirely. Retail pharmacy becomes the front line. CVS, Walgreens, and specialty mail-order pharmacies suddenly matter more. The pharmacy benefit manager space gets repriced. Companies with the scale and infrastructure to handle high-volume, recurring oral prescriptions have a structural advantage that wasn’t there two years ago.
Lilly is also evaluating orforglipron in late-stage studies in other disease areas like obstructive sleep apnea, osteoarthritis pain of the knee, stress urinary incontinence, and hypertension. That pipeline expansion is the longer story. Foundayo’s obesity approval is the opening chapter.
GlobalData forecasts that orforglipron will claim status as a mega-blockbuster seller in 2031, bringing in sales of $13 billion during that year. That’s a projection. Projections are wrong. But the direction of travel here isn’t. Medicare Part D coverage begins July 1. The commercial savings card makes it accessible at $25 a month. The barriers that kept 90% of eligible patients on the sidelines are coming down, one by one.
The real question is not whether Lilly or Novo wins. It’s whether anyone is positioned for what happens when 30 million new patients start filling monthly prescriptions. That infrastructure question hasn’t been seriously priced.
